Get started
NEUREN PHARMACEUTICALS LIMITEDNEUREN PHARMACEUTICALS LIMITEDNEUREN PHARMACEUTICALS LIMITED

NEUREN PHARMACEUTICALS LIMITED

No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Technicals Forecast Seasonals

NEU fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

Neuren Pharmaceuticals Ltd. engages in the development of new therapies for neurodevelopmental disorders that emerge in early childhood. It operates through the Commercial Products, and Research and Development segments. The Commercial Products segment refers to the milestone and royalty revenue from license of intellectual property. The Research and Development segment focuses on the development of pharmaceutical products for the treatment of neurodevelopmental disorders. The company was founded on December 17, 2001 and is headquartered in Camberwell, Australia.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
NEU has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company